Former Sanofi I&I exec Frédéric Marrache launches Bionyra with $165M to chase TL1A targets in IBD and eczema.
Frédéric Marrache, Bionyra CEO (courtesy Bionyra)
June 22, 2026 07:00 AM EDTUpdated 08:07 AM
FinancingStartupsChina
Bionyra's $165M launch: A Sanofi alum, I&I candidates from China, one big catch-up
Kyle LaHucik
Bionyra brings in $165M for next-generation immune drugs
La biotech française Bionyra lève 143 millions d’euros pour s’attaquer aux maladies inflammatoires chroniques
Sanofi names new R&D head as it tries to jumpstart pipeline
Nortiva purrs into action with long-acting Lynx platform salvaged from Langer startup
Lys Therapeutics Raises More Than €25 Million to Advance LYS241 Toward Clinical Development in Neurology
ABIONYX Pharma Announces the Success of its Financing for a Total Maximum Amount of EUR 33 M
Le fonds wavrien Vives participe à une Série A de 143 millions dans la biotech Bionyra Pharma
Biogen adds more immune drugs in $1B buyout of secretive startup Raythera
Sanofi swaps R&D leaders; Merck’s Prometheus deal pays dividends
Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor
The biotech, co-founded by Sofinnova Partners and a former Sanofi immunology R&D head, is testing new biologics against common…
Things are happening fast at BridgeBio as it plugs away at the launch of blockbuster-in-waiting Attruby and prepares to…
Nura Bio raises $73.8M Series B to advance oral SARM1 inhibitors NB-4746 in ALS and NB-9402 through early clinical trials.
BridgeBio raises $1B via preferred equity from Sixth Street and KKR's HealthCare Royalty, stockpiling cash ahead of three drug…
Avec cette enveloppe, la biotech veut amorcer la mise au point d’une nouvelle génération de biothérapies destinées à soigner les…
Bay Area biotech SonoThera is bubbling to a clinical boil after raising a
